Health Economics and HTA and its role in pricing and reimbursement, pipeline and in-lisencing evaluations as well as portfolio and company valuations in the biotech and pharmaceutical sector is ever increasing. While I was searching the web for various news on the topic, I actually couldn't find a blog that offers a platform of exchange among professionals in this field around the various topics - so there we go now and I hope you enjoy the information...
Cheers
Ulf
10.12.2011
German Law Has Companies Weighing Whether to Sell New Drugs in Europe's Largest Market
Dear All,
there is a very interesting podcast on the AMNOG implications and recent developments from the Burrill report.
No comments:
Post a Comment